Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kelly S. Doran, Erin J. Engelson, Arya Khosravi, Heather C. Maisey, Iris Fedtke, Ozlem Equils, Kathrin S. Michelsen, Moshe Arditi, Andreas Peschel, Victor Nizet
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2499–2507 doi:10.1172/JCI23829
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

In vivo analysis of the ΔiagA mutant using a mouse model. Deletion of iagA does not effect GBS survival in mouse blood (A) or sensitivity to antimicrobial peptide CRAMP (B) but does render GBS less pathogenic in vivo. Groups of 10 mice were inoculated i.v. with WT or ΔiagA GBS strains. (C) Kaplan-Meier survival plot. (D) Bacterial counts (CFU) in mouse blood, brain, and spleen at time of death of WT (circles) and ΔiagA (squares); filled symbols represent mice that died before the experiemental endpoint. Histopathology of H&E- (EH) or Gram-stained (F) brain tissues of individual mice (identified by arrows in D). (E and G) Samples from mice infected with WT GBS show meningeal thickening and cellular infiltration (open arrows) and bacterial microabscess formation (filled arrow). (F) Gram stain of mouse infected with WT GBS. (H) A sample from the mouse infected with the iagA mutant shows normal brain histopathology.